Literature DB >> 10102786

Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys.

J D Jentsch1, J R Taylor, D E Redmond, J D Elsworth, K D Youngren, R H Roth.   

Abstract

D4 dopamine receptors (DRs) are enriched in the primate prefrontal cortex, a brain region implicated in cognitive processes, and mesoprefrontal dopaminergic systems appear to be involved in modulating some cognitive functions of the prefrontal cortex. Despite anatomical localization of D4 DRs within the frontal cortex, the role of these receptors, specifically, in the regulation of cognition or behavior in primates is unknown. In these studies, we sought to learn whether specific antagonism of D4 DRs would affect performance of a task dependent on the frontostriatal system. The effects of NGD94-1 (2-phenyl-4(5)-[4-(2-pyrimidinyl)-piperazin-1-yl)-methyl]-imidazol e dimaleate), a potent and selective D4 DR antagonist and haloperidol, a non-specific D2-like DR antagonist, on the performance of an object retrieval/detour task by monkeys were examined. The effects of these antagonists on the object retrieval task were evaluated in normal control monkeys and in subjects repeatedly exposed to phencyclidine (PCP), to induce frontal cortical dopaminergic and cognitive dysfunction. NGD94-1 (1-5 mg/kg) reversed the cognitive deficits of PCP pre-treated monkeys, whereas haloperidol (25 microg/kg) exacerbated PCP-induced performance impairments. A low dose of NGD94-1 failed to affect performance of control subjects, while both haloperidol and a high dose of NGD94-1 impaired control performance. These data show, for the first time, that D4 DRs modulate the cognitive functions of the frontostriatal system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102786     DOI: 10.1007/s002130050865

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  27 in total

1.  Cognition, schizophrenia, and the atypical antipsychotic drugs.

Authors:  H Y Meltzer; S Park; R Kessler
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 2.  The dopamine D4 receptor: biochemical and signalling properties.

Authors:  Pieter Rondou; Guy Haegeman; Kathleen Van Craenenbroeck
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

3.  Restoration of glutamatergic transmission by dopamine D4 receptors in stressed animals.

Authors:  Eunice Y Yuen; Ping Zhong; Xiangning Li; Jing Wei; Zhen Yan
Journal:  J Biol Chem       Date:  2013-07-24       Impact factor: 5.157

Review 4.  Cognitive effects of second-generation antipsychotics: current insights into neurochemical mechanisms.

Authors:  Fabio Fumagalli; Angelisa Frasca; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 5.  Antipsychotic medications and the elderly: effects on cognition and implications for use.

Authors:  M J Byerly; M T Weber; D L Brooks; L R Snow; M A Worley; E Lescouflair
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 6.  Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia.

Authors:  Nurith Amitai; Athina Markou
Journal:  Biol Psychiatry       Date:  2010-05-21       Impact factor: 13.382

7.  F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.

Authors:  R Depoortère; A L Auclair; L Bardin; L Bruins Slot; M S Kleven; F Colpaert; B Vacher; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

8.  Dopamine D4 Receptors Regulate GABAA Receptor Trafficking via an Actin/Cofilin/Myosin-dependent Mechanism.

Authors:  Nicholas M Graziane; Eunice Y Yuen; Zhen Yan
Journal:  J Biol Chem       Date:  2009-01-29       Impact factor: 5.157

9.  Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey.

Authors:  Joshua D Vardigan; Christopher E Cannon; Vanita Puri; Mandy Dancho; AmyJo Koser; Marion Wittmann; Scott D Kuduk; John J Renger; Jason M Uslaner
Journal:  Psychopharmacology (Berl)       Date:  2014-12-10       Impact factor: 4.530

Review 10.  Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

Authors:  Patricia S Goldman-Rakic; Stacy A Castner; Torgny H Svensson; Larry J Siever; Graham V Williams
Journal:  Psychopharmacology (Berl)       Date:  2004-04-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.